Rigel Pharmaceuticals Cash on Hand 2012-2025 | RIGL

Rigel Pharmaceuticals cash on hand from 2012 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Rigel Pharmaceuticals Annual Cash on Hand
(Millions of US $)
2024 $77
2023 $57
2022 $58
2021 $125
2020 $57
2019 $98
2018 $129
2017 $116
2016 $75
2015 $126
2014 $143
2013 $212
2012 $298
2011 $248
Rigel Pharmaceuticals Quarterly Cash on Hand
(Millions of US $)
2025-09-30 $137
2025-06-30 $108
2025-03-31 $77
2024-12-31 $77
2024-09-30 $61
2024-06-30 $49
2024-03-31 $50
2023-12-31 $57
2023-09-30 $62
2023-06-30 $64
2023-03-31 $59
2022-12-31 $58
2022-09-30 $82
2022-06-30 $89
2022-03-31 $108
2021-12-31 $125
2021-09-30 $143
2021-06-30 $153
2021-03-31 $39
2020-12-31 $57
2020-09-30 $73
2020-06-30 $92
2020-03-31 $96
2019-12-31 $98
2019-09-30 $107
2019-06-30 $112
2019-03-31 $128
2018-12-31 $129
2018-09-30 $116
2018-06-30 $135
2018-03-31 $94
2017-12-31 $116
2017-09-30 $68
2017-06-30 $82
2017-03-31 $98
2016-12-31 $75
2016-09-30 $85
2016-06-30 $95
2016-03-31 $104
2015-12-31 $126
2015-09-30 $134
2015-06-30 $144
2015-03-31 $161
2014-12-31 $143
2014-09-30 $158
2014-06-30 $176
2014-03-31 $195
2013-12-31 $212
2013-09-30 $231
2013-06-30 $252
2013-03-31 $272
2012-12-31 $298
2012-09-30 $184
2012-06-30 $203
2012-03-31 $223
2011-12-31 $248
2011-09-30 $266
2011-06-30 $279
2011-03-31 $156
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.623B $0.179B
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $100.311B 35.03
Takeda Pharmaceutical (TAK) Japan $58.739B 11.54
Zoetis (ZTS) United States $55.814B 19.73
BeOne Medicines - (ONC) Switzerland $37.951B 201.20
Sandoz Group AG (SDZNY) Switzerland $37.721B 0.00
Daiichi Sankyo, - (DSNKY) Japan $36.542B 18.20
United Therapeutics (UTHR) United States $20.394B 17.95
Shionogi (SGIOY) Japan $19.736B 15.26
Merck (MKKGY) Germany $19.561B 12.06
IPSEN (IPSEY) France $15.077B 0.00
Ionis Pharmaceuticals (IONS) United States $13.055B 0.00
Neurocrine Biosciences (NBIX) United States $12.457B 26.92
Summit Therapeutics (SMMT) United States $11.536B 0.00
Orion OYJ (ORINY) Finland $11.214B 19.47
Madrigal Pharmaceuticals (MDGL) United States $10.554B 0.00
Eisai (ESAIY) $9.636B 0.00
Ono Pharmaceutical (OPHLF) Japan $8.769B 20.98
Stevanato Group S.p.A (STVN) Italy $4.849B 27.14
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.828B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $4.659B 22.12
Crinetics Pharmaceuticals (CRNX) United States $4.363B 0.00
Indivior Pharmaceuticals (INDV) United States $4.323B 17.64
Corcept Therapeutics (CORT) United States $4.204B 45.42
NewAmsterdam Pharma (NAMS) Netherlands $3.927B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $3.322B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.990B 9.54
Hypermarcas (HYPMY) Brazil $2.658B 18.24
Dyne Therapeutics (DYN) United States $2.220B 0.00
Guardian Pharmacy Services (GRDN) United States $2.119B 40.80
Avadel Pharmaceuticals (AVDL) Ireland $2.113B 0.00
Soleno Therapeutics (SLNO) United States $2.000B 0.00
Ocular Therapeutix (OCUL) United States $1.933B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.876B 22.23
Harrow (HROW) United States $1.766B 108.39
Ardelyx (ARDX) United States $1.669B 0.00
Enliven Therapeutics (ELVN) United States $1.586B 0.00
Oruka Therapeutics (ORKA) United States $1.559B 0.00
Definium Therapeutics (DFTX) United States $1.552B 0.00
Amylyx Pharmaceuticals (AMLX) United States $1.551B 0.00
Relay Therapeutics (RLAY) United States $1.548B 0.00
Nektar Therapeutics (NKTR) United States $1.451B 0.00
Collegium Pharmaceutical (COLL) United States $1.447B 7.17
BioCryst Pharmaceuticals (BCRX) United States $1.425B 84.50
Evotec AG (EVO) Germany $1.247B 0.00
Savara (SVRA) United States $1.139B 0.00
Xeris Biopharma Holdings (XERS) United States $1.132B 0.00
Theravance Biopharma (TBPH) United States $0.990B 41.55
Cronos Group (CRON) Canada $0.988B 0.00
Aktis Oncology (AKTS) United States $0.900B 0.00
ARS Pharmaceuticals (SPRY) United States $0.875B 0.00
Xencor (XNCR) United States $0.828B 0.00
Esperion Therapeutics (ESPR) United States $0.820B 0.00
KalVista Pharmaceuticals (KALV) United States $0.754B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.732B 17.31
Bioventus (BVS) United States $0.684B 14.02
ProKidney (PROK) United States $0.596B 0.00
Lyell Immunopharma (LYEL) United States $0.549B 0.00
4D Molecular Therapeutics (FDMT) United States $0.534B 0.00
Altimmune (ALT) United States $0.511B 0.00
Siga Technologies (SIGA) United States $0.486B 6.66
Zevra Therapeutics (ZVRA) United States $0.479B 0.00
Elite Pharmaceuticals (ELTP) United States $0.474B 0.00
Organogenesis (ORGO) United States $0.473B 0.00
Nature's Sunshine Products (NATR) United States $0.471B 28.03
Lexeo Therapeutics (LXEO) United States $0.461B 0.00
Aquestive Therapeutics (AQST) United States $0.445B 0.00
USANA Health Sciences (USNA) United States $0.382B 10.66
Aclaris Therapeutics (ACRS) United States $0.346B 0.00
Protara Therapeutics (TARA) United States $0.336B 0.00
Akebia Therapeutics (AKBA) United States $0.321B 0.00
Aldeyra Therapeutics (ALDX) United States $0.318B 0.00
Cybin (HELP) Canada $0.304B 0.00
Relmada Therapeutics (RLMD) United States $0.273B 0.00
Minerva Neurosciences (NERV) United States $0.271B 0.00
Avalo Therapeutics (AVTX) United States $0.264B 0.00
Enlivex Therapeutics (ENLV) Israel $0.263B 0.00
Larimar Therapeutics (LRMR) United States $0.261B 0.00
Journey Medical (DERM) United States $0.257B 0.00
OmniAb (OABI) United States $0.245B 0.00
Profound Medical (PROF) Canada $0.240B 0.00
Achieve Life Sciences (ACHV) Canada $0.224B 0.00
MediWound (MDWD) Israel $0.222B 0.00
Context Therapeutics (CNTX) United States $0.211B 0.00
Heron Therapeutics (HRTX) United States $0.211B 0.00
Silence Therapeutics (SLN) United Kingdom $0.210B 0.00
Surrozen (SRZN) United States $0.210B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.184B 0.00
Innate Pharma SA (IPHYF) France $0.181B 0.00
Galectin Therapeutics (GALT) United States $0.178B 0.00
AleAnna (ANNA) United States $0.171B 0.00
Karyopharm Therapeutics (KPTI) United States $0.157B 0.00
Century Therapeutics (IPSC) United States $0.153B 0.00
Prelude Therapeutics (PRLD) United States $0.140B 0.00
VAXART, INC (VXRT) United States $0.136B 0.00
Unicycive Therapeutics (UNCY) United States $0.133B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.133B 0.00
Avita Medical (RCEL) United States $0.127B 0.00
Inhibikase Therapeutics (IKT) United States $0.126B 0.00
Cardiol Therapeutics (CRDL) Canada $0.116B 0.00
Korro Bio (KRRO) United States $0.105B 0.00
Cassava Sciences (SAVA) United States $0.101B 0.00
Incannex Healthcare (IXHL) Australia $0.093B 0.00
Vivani Medical (VANI) United States $0.092B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.091B 0.00
Champions Oncology (CSBR) United States $0.084B 35.76
Pyxis Oncology (PYXS) United States $0.081B 0.00
Assertio Holdings (ASRT) United States $0.079B 0.00
PolyPid (PYPD) Israel $0.070B 0.00
Gain Therapeutics (GANX) United States $0.070B 0.00
HST Global (HSTC) United States $0.069B 0.00
Rafael Holdings (RFL) United States $0.062B 0.00
PMV Pharmaceuticals (PMVP) United States $0.059B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.058B 48.50
Fractyl Health (GUTS) United States $0.057B 0.00
BioNxt Solutions (BNXTF) Canada $0.057B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.056B 0.00
Dominari Holdings (DOMH) United States $0.055B 0.00
NRx Pharmaceuticals (NRXP) United States $0.053B 0.00
Acrivon Therapeutics (ACRV) United States $0.051B 0.00
Nutriband (NTRB) United States $0.050B 0.00
Lipocine (LPCN) United States $0.048B 0.00
ElectroCore (ECOR) United States $0.043B 0.00
Lite Strategy (LITS) United States $0.041B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Plus Therapeutics (PSTV) United States $0.038B 0.00
Talphera (TLPH) United States $0.038B 0.00
Telomir Pharmaceuticals (TELO) United States $0.037B 0.00
Mural Oncology (MURA) Ireland $0.035B 0.00
SCYNEXIS (SCYX) United States $0.031B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.030B 0.00
TherapeuticsMD (TXMD) United States $0.027B 0.00
Wellgistics Health (WGRX) United States $0.025B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.024B 0.00
Natural Alternatives (NAII) United States $0.022B 0.00
Jupiter Neurosciences (JUNS) United States $0.020B 0.00
VYNE Therapeutics (VYNE) United States $0.019B 0.00
Phio Pharmaceuticals (PHIO) United States $0.018B 0.00
Scienture Holdings (SCNX) United States $0.018B 0.00
Klotho Neurosciences (KLTO) United States $0.016B 0.00
Citius Pharmaceuticals (CTXR) United States $0.016B 0.00
Traws Pharma (TRAW) United States $0.015B 0.02
Iterum Therapeutics (ITRM) Ireland $0.015B 0.00
Vyome Holdings (HIND) United States $0.015B 0.00
Cosmos Health (COSM) United States $0.014B 0.00
Vivos Therapeutics (VVOS) United States $0.014B 0.00
Mannatech (MTEX) United States $0.014B 0.00
BioLineRx (BLRX) Israel $0.013B 0.00
Liminatus Pharma (LIMN) United States $0.012B 0.00
Tempest Therapeutics (TPST) United States $0.012B 0.00
CASI Pharmaceuticals (CASI) China $0.010B 0.00
Inotiv (NOTV) United States $0.010B 0.00
BioVie (BIVI) United States $0.010B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.008B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.008B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
Ainos (AIMD) United States $0.007B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.007B 0.00
Biomerica (BMRA) United States $0.007B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Mangoceuticals (MGRX) United States $0.006B 0.00
Alaunos Therapeutics (TCRT) United States $0.006B 0.00
Redhill Biopharma (RDHL) Israel $0.005B 0.00
Heatwurx (PCSA) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Indaptus Therapeutics (INDP) United States $0.004B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.004B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Ernexa Therapeutics (ERNA) United States $0.003B 0.00
China SXT Pharmaceuticals (SXTC) China $0.003B 0.00
Lyra Therapeutics (LYRA) United States $0.002B 0.00
Jaguar Animal Health (JAGX) United States $0.002B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
CDT Equity (CDT) United States $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
PainReform (PRFX) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.000B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00